BTIG maintained a Buy rating on Arcturus Therapeutics on Thursday. The firm lowered its price target to $20 from $23. This adjustment reflects the company’s transition to the LUNAR 2.0 delivery platform for its OTC deficiency treatment. Analysts noted that while lead candidate ARCT-810 showed activity, the platform shift introduces new variables.
Citigroup upgraded Arcturus Therapeutics to Buy from Neutral. The firm raised its price target to $20 from $8. This upgrade follows the presentation of Phase 2 clinical data for ARCT-810. These divergent actions highlight Wall Street's uncertainty regarding the company's pipeline valuation and platform evolution.